Axovant Gene Therapies Ltd. (AXON)

Jim Cramer says investors need to be cautious, as trade tensions are just one of the things causing markets to whiplash. But he's got your game plan for next week.

In recent trading, shares of Axovant Sciences Ltd have crossed above the average analyst 12-month target price of $4.60, changing hands for $4.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

The Nasdaq sets a record closing high for three straight sessions.

Law Offices of Howard G. Smith commences an investigation on behalf of Axovant Sciences Ltd.

Chief executive David Hung resigned from the Basel, Switzerland, biotech after just 10 months on the job.

Even with Monday's sharp reversal, Jim Cramer says he still likes this market.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Axovant Sciences Ltd , where a total volume of 10,433 contracts has been traded thus far today, a contract volume which is representative of approximately 1.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 84.2% of AXON's average daily trading volume over the past month, of 1.2 million shares.

Investors considering a purchase of Axovant Sciences Ltd stock, but cautious about paying the going market price of $5.06/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2018 put at the $5 strike, which has a bid at the time of this writing of $1.40.

Softbank founder Masayoshi Son is placing big bets on artificial intelligence applications from chips to cars to workplace chats. He'll likely need more than one $100 billion fund to do it.

Axovant shares were up in premarket trading on Sept. 27 after plummeting on Tuesday on the heels of the announcement that the company's Phase 3 study of intepirdine in patients with Alzheimer's disease did not achieve its co-primary efficacy endpoints.

The company said Tuesday its Phase 3 study of intepirdine in patients with Alzheimer's disease did not achieve its co-primary efficacy endpoints.Meanwhile, shares of Genocea Biosciences Inc. were down, after the Cambridge, Mass.-based company announced a shift to immuno-oncology and a focus on developing neoantigen cancer vaccines.

Carnival shares jump after beating quarterly estimates but Adidas stock slumped following an investigation into a NCAA Bribery Scandal.

Stocks are higher. Here's how the market is trading in the afternoon session on Tuesday.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Axovant Sciences Ltd , where a total volume of 43,808 contracts has been traded thus far today, a contract volume which is representative of approximately 4.4 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 624.2% of AXON's average daily trading volume over the past month, of 701,830 shares.

Top names.

This is one of those days when it may pay to walk away.

Biotechnology is showing little relative strength and oil is up again, but there isn't much going on with themes.

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.